Valosin-containing protein immunoreactivity in tauopathies, synucleinopathies, polyglutamine diseases and intranuclear inclusion body disease

• Published in: Neuropathology Vol. 33; no. 6; pp. 637 - 644
• Main Authors: Mori, Fumiaki, Tanji, Kunikazu, Toyoshima, Yasuko, Sasaki, Hidenao, Yoshida, Mari, Kakita, Akiyoshi, Takahashi, Hitoshi, Wakabayashi, Koichi
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01.12.2013
• Subjects: Adenosine Triphosphatases - metabolism; Aged; Aged, 80 and over; Amyotrophic lateral sclerosis; Brain - metabolism; Brain - pathology; Cell Cycle Proteins - metabolism; Female; Humans; Immunohistochemistry; Intranuclear Inclusion Bodies - metabolism; Intranuclear Inclusion Bodies - pathology; Lewy body; Male; Marinesco body; Middle Aged; Neurodegenerative Diseases - metabolism; Neurodegenerative Diseases - pathology; neuronal nuclear inclusion; polyglutamine disease; Valosin Containing Protein; Marinesco body; neuronal nuclear inclusion; valosin-containing protein; Lewy body; polyglutamine disease
• ISSN: 0919-6544; 1440-1789; 1440-1789
• DOI: 10.1111/neup.12050

Valosin‐containing protein (VCP) is associated with multiple cellular functions, including ubiquitin‐dependent protein degradation. Mutations in VCP are known to cause inclusion body myopathy with Paget's disease and frontotemporal dementia and familial amyotrophic lateral sclerosis (fALS; ALS14), both of which are characterized by trans‐activation response DNA protein 43 (TDP‐43)‐positive neuronal cytoplasmic and nuclear inclusions. Recently, immunoreactivity for fALS‐associated proteins (TDP‐43, fused in sarcoma (FUS), optineurin and ubiquilin‐2) were reported to be present in cytoplasmic and nuclear inclusions in various neurodegenerative diseases. However, the extent and frequency of VCP‐immunoreactive structures in these neurodegenerative diseases are uncertain. We immunohistochemically examined the brains of 72 cases with neurodegenerative diseases and five control cases. VCP immunoreactivity was present in Lewy bodies in Parkinson's disease and dementia with Lewy bodies, and neuronal nuclear inclusions in five polyglutamine diseases and intranuclear inclusion body disease, as well as in Marinesco bodies in aged control subjects. However, other neuronal and glial cytoplasmic inclusions in tauopathies and TDP‐43 proteinopathies were unstained. These findings suggest that VCP may have common mechanisms in the formation or degradation of cytoplasmic and nuclear inclusions of neurons, but not of glial cells, in several neurodegenerative conditions.